ZURA BIO LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.79 USD | +2.35% |
|
+3.23% | +2.57% |
| May. 10 | Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating | MT |
| May. 09 | Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 322M |
|---|---|---|---|---|---|
| Net income 2024 * | -36M | Net income 2025 * | -59M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-9.97
x | P/E ratio 2025 * |
-6.29
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.2% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.35% | ||
| 1 week | +3.23% | ||
| Current month | +12.18% | ||
| 1 month | +42.56% | ||
| 3 months | +20.96% | ||
| 6 months | +8.86% | ||
| Current year | +2.57% |
1 week
4.52
5.41
1 month
3.005.41
Current year
2.005.41
1 year
2.0013.00
3 years
2.0037.55
5 years
2.0037.55
10 years
2.0037.55
| Managers | Title | Age | Since |
|---|---|---|---|
Someit Sidhu
FOU | Founder | 34 | 22-01-17 |
Robert Lisicki
CEO | Chief Executive Officer | 57 | Jan. 07 |
Verender Badial
DFI | Director of Finance/CFO | 51 | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Amit Munshi
CHM | Chairman | 56 | 23-02-28 |
Steven Schoch
BRD | Director/Board Member | 64 | 23-02-28 |
Sandeep Kulkarni
BRD | Director/Board Member | 43 | 22-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.53% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 5.16 | +7.72% | 256,541 |
| 24-05-13 | 4.79 | +2.35% | 162,379 |
| 24-05-10 | 4.68 | +1.74% | 164,766 |
| 24-05-09 | 4.6 | -2.34% | 101,720 |
| 24-05-08 | 4.71 | +1.51% | 93,882 |
End-of-day quote Nasdaq, May 12, 2024
More quotes
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.16
USD
Average target price
17.17
USD
Spread / Average Target
+232.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.57% | 322M | |
| +5.33% | 111B | |
| +12.11% | 106B | |
| -12.56% | 22.24B | |
| -3.29% | 21.25B | |
| -5.71% | 18.97B | |
| -35.21% | 18.52B | |
| -10.86% | 16.81B | |
| +37.57% | 12.54B | |
| -26.24% | 8.09B |
- Stock Market
- Equities
- ZURA Stock